Navigation Links
ERT Reports First Quarter 2011 Operating Results
Date:5/2/2011

for up to one year on either site.  

About eResearchTechnology, Inc.ERT (www.ert.com) is a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.  It is the market leader for centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes electronic patient reported outcomes (ePRO) in multiple modalities across all phases of clinical research.

This release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect our current views as to future events and financial performance with respect to our operations.  These statements can be identified by the fact that they do not relate strictly to historical or current facts.  They use words such as "aim," "anticipate," "are confident," "estimate," "expect," "will be," "will continue," "will likely result," "project," "intend," "plan," "believe," "look to" and other words and terms of similar meaning in conjunction with a discussion of future operating or financial performance.  

These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements.  Factors that might cause such a difference include: unfavorable economic conditions; our ability to obtain new contracts and accurately estimate net revenues, our positive outlook for future bookings, variability in size, scope and duration of projects and internal issues at the sponsoring client; our ability to successfully integrate the RS or any future acquisitions; competitive factors in the market for our centralized services; changes in the bio-pharmaceutical and healthcare industries to which we sell our solutions; technological development; and market demand
'/>"/>

SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... MENLO PARK, Calif. , May ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, presented ... of Cancer Research (AACR) Advances in Brain Cancer ... lead product candidate VAL-083 (dianhydrogalactitol) to ...
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and Company ... ) today announced that they have entered into a ... efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, ... Receptor 2 antiangiogenic cancer medicine. The planned study will ... advanced solid tumors. The Phase I study ...
(Date:5/29/2015)...  World-renowned prostate surgeon and New York Urologist, Dr. ... MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive prostate ... at Lenox Hill Hospital is the only center using ... New York City . We,ve seen tremendous improvement in ... use of an MRI makes for a much more accurate ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... Life Spine, a medical device company that designs, ... of spine disorders, today announced that the Company presented ... technologies at the 6th Annual Spine Technology Summit, hosted ... in Napa, California. "Life Spine has an ...
... 13, 2011 Cookeville-based Aphena Pharma Solutions Inc., a leading ... to announce that on June 1, Mary G. Foster, PharmD ... — will join the company as its Corp. VP of ... Aphena to shape its vision, plan long-term goals, and further ...
Cached Medicine Technology:Top Industry Professional Joins Aphena as Head of Quality & Regulatory Affairs 2
(Date:5/29/2015)... Based in St. Louis, Missouri La La Land ... a couple of months now and are really helping spread ... “I’m not misbehaving, I have Autism, please be understanding” is ... autistic child in order to start a conversation and ultimately ... they raising awareness through the autism awareness shirts which can ...
(Date:5/29/2015)... Island (PRWEB) May 29, 2015 The ... 2015. The event, now closed to new registration, starts ... Adams. This exciting competitive running event demonstrates the ... to create a public benefit – in this case, ... coastal views around the famed Ocean Drive and passes ...
(Date:5/29/2015)... May 29, 2015 Dot Hill can mark one ... resident of Lake Prince Woods retirement community is the ... Virginia Beach, Virginia. , “It was great fun!”, she exclaimed. ... didn’t want me to so they thought this would be ok.” ... into a vertical wind tunnel,” she described. “I don’t remember ...
(Date:5/29/2015)... Chicago, IL (PRWEB) May 29, 2015 ... team conducted research, choosing systems that have several awards ... healthcare leaders on what systems stood out to them ... considered for inclusion as well. , The 50 Great ... organizations: , Adventist Health System (Altamonte Springs, Fla.) , ...
(Date:5/29/2015)... 2015 Intermountain Healthcare of ... Stratus Video Interpreting for on-demand ... communication and timely care for patients with ... Stratus’ video remote interpreting (VRI) services will ... to quickly access qualified medical interpretation in ...
Breaking Medicine News(10 mins):Health News:La La Land Shirts Is Busy Spreading Autism Awareness with Complimentary Shipping on Their New Shirt 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3Health News:Indoor Skydiving Brings Thrills to Seniors 2Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 2Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4
... ... Asia Research News 2010 is now available online and in print. , ... (PRWebUK) June 24, 2010 -- We are pleased ... Asia Research News , , , , ,The magazine features interesting on-going research from ...
... Doheny HealthDay Reporter , THURSDAY, June 24 ... to reduce the risk of invasive breast cancer by ... a woman is considering bisphosphonate use for bone, this ... Chlebowski, a clinical oncologist at the Los Angeles Biomedical ...
... HealthDay Reporter , THURSDAY, June 24 (HealthDay News) -- Ninety ... a new government report reveals. In fact, salt is ... people to consume less. Too much salt can increase your ... and stroke. "Nine in 10 American adults consume more ...
... readily and safely distinguished the brains of Alzheimer,s disease ... the doors to making such imaging available beyond facilities ... reported by a Johns Hopkins team in the June ... better ways to distinguish Alzheimer,s from other types of ...
... Medical Centre in The Netherlands found that cyclosporine treatment ... de novo cancer in liver transplant patients. Full details ... , a journal published by Wiley-Blackwell on behalf of ... (AASLD). The 1-year survival rate after liver transplantation ...
... studies have shown that antiviral treatment reduces the incidence ... B (CHB). But now, researchers from the Division of ... that the antiviral therapy also prevents recurrence of HCC ... care for patients with HCC is local ablation of ...
Cached Medicine News:Health News:Asia Research News 2010 2Health News:Asia Research News 2010 3Health News:Bone-Building Pills Appear to Lower Invasive Breast Cancer Risk 2Health News:Bone-Building Pills Appear to Lower Invasive Breast Cancer Risk 3Health News:Most Americans Get Too Much Salt 2Health News:Most Americans Get Too Much Salt 3Health News:Novel radiotracer shines new light on the brains of Alzheimer's disease patients 2Health News:Higher cancer rates found in liver transplant patients receiving cyclosporine for immunosuppression 2Health News:Higher cancer rates found in liver transplant patients receiving cyclosporine for immunosuppression 3Health News:Silencing hepatitis B virus prevent recurrence of liver cancer 2
1.2% Tryptone, 2.4% Yeast Extract, 1.6% Glycerol, 100 ml of 10x Phosphate buffer supplement....
5.0% Casein digest (NZ amine), 2.5% Sodium Chloride, 2.5% Yeast Extract....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
Medicine Products: